Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 56 Breast Neoplasms 49 Ovarian Neoplasms 31 Triple Negative Breast Neoplasms 27 Endometrial Neoplasms 25 Lung Neoplasms 24 Fallopian Tube Neoplasms 22 Neoplasm Metastasis 21 Squamous Cell Carcinoma of Head and Neck 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Neoplasms 14 Esophageal Squamous Cell Carcinoma 12 Esophageal Neoplasms 12 Carcinoma, Ovarian Epithelial 9 Stomach Neoplasms 8 Head and Neck Neoplasms 8 Colorectal Neoplasms 8 Carcinoma 7 Adenocarcinoma Of Esophagus 7 Peritoneal Neoplasms 6 Adenocarcinoma 6 Uterine Cervical Neoplasms 5 Melanoma 5 Oropharyngeal Neoplasms 4 Cholangiocarcinoma 4 Carcinoma, Transitional Cell 4 Small Cell Lung Carcinoma 3 Recurrence 3 Pancreatic Neoplasms 3 Mouth Neoplasms 3

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Paclitaxel × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡